Here are four things to know.
- Mallinckrodt hired investment bank Credit Suisse Group to launch a sales process for the generic drug unit, sources told Reuters Tuesday.
- The sources — who note the sales talks do not guarantee a divestiture — said a deal could be worth up to $2 billion, according to the report.
- The deal would align with Mallinckrodt’s efforts to shift focus away from generics to its portfolio of branded specialty drugs, which generate the majority of its revenues, reports Reuters.
- Mallinckrodt and Credit Suisse declined Reuters’ request for comment.
More articles on supply chain:
Pharma spent $78M on lobbying so far this year: 4 statistics
Dr. Scott Gottlieb talks drug price strategies, FDA hiring freeze: 4 takeaways
Sawai Pharma to acquire Upsher-Smith’s generic drug unit for $1B
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
